Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
BURNABY, British Columbia, May 01, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.
To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4982979. The webcast will be broadcast live on the “Investors” section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as epilepsy, migraine and pain. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Vice President, Corporate Affairs & Investor Relations
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]
